PMID- 16858650
OWN - NLM
STAT- MEDLINE
DCOM- 20070105
LR  - 20220317
IS  - 0724-8741 (Print)
IS  - 0724-8741 (Linking)
VI  - 23
IP  - 8
DP  - 2006 Aug
TI  - Heparin immobilized porous PLGA microspheres for angiogenic growth factor 
      delivery.
PG  - 1835-41
AB  - PURPOSE: Heparin immobilized porous poly(D,L-lactic-co-glycolic acid) (PLGA) 
      microspheres were prepared for sustained release of basic fibroblast growth 
      factor (bFGF) to induce angiogenesis. MATERIALS AND METHODS: Porous PLGA 
      microspheres having primary amine groups on the surface were prepared using an 
      oil-in-water (O/W) single emulsion method using Pluronic F-127 as an extractable 
      porogen. Heparin was surface immobilized via covalent conjugation. bFGF was 
      loaded into the heparin functionalized (PLGA-heparin) microspheres by a simple 
      dipping method. The bFGF loaded PLGA-heparin microspheres were tested for in 
      vitro release and in vivo angiogenic activity. RESULTS: PLGA microspheres with an 
      open-porous structure were formed. The amount of conjugated amine group onto the 
      microspheres was 1.93+/-0.01 nmol/mg-microspheres, while the amount of heparin 
      was 95.8 pmol/mg-microspheres. PLGA-heparin microspheres released out bFGF in a 
      more sustained manner with a smaller extent of initial burst than PLGA 
      microspheres, indicating that surface immobilized heparin controlled the release 
      rate of bFGF. Subcutaneous implantation of bFGF loaded PLGA-heparin microspheres 
      in mice significantly induced the formation of new vascular microvessels. 
      CONCLUSIONS: PLGA microspheres with an open porous structure allowed significant 
      amount of heparin immobilization and bFGF loading. bFGF loaded PLGA-HP 
      microspheres showed sustained release profiles of bFGF in vitro, demonstrating 
      reversible and specific binding of bFGF to immobilized heparin. They also induced 
      local angiogenesis in vivo in an animal model.
FAU - Chung, Hyun Jung
AU  - Chung HJ
AD  - Department of Biological Sciences, Korea Advanced Institute of Science and 
      Technology, Daejeon 305-701, South Korea.
FAU - Kim, Hong Kee
AU  - Kim HK
FAU - Yoon, Jun Jin
AU  - Yoon JJ
FAU - Park, Tae Gwan
AU  - Park TG
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Pharm Res
JT  - Pharmaceutical research
JID - 8406521
RN  - 0 (Amines)
RN  - 0 (Excipients)
RN  - 0 (Polymers)
RN  - 103107-01-3 (Fibroblast Growth Factor 2)
RN  - 1SIA8062RS (Polylactic Acid-Polyglycolic Acid Copolymer)
RN  - 26009-03-0 (Polyglycolic Acid)
RN  - 33X04XA5AT (Lactic Acid)
RN  - 9005-49-6 (Heparin)
SB  - IM
MH  - Amines/chemistry
MH  - Animals
MH  - Excipients
MH  - Fibroblast Growth Factor 2/*administration & dosage/chemistry/*pharmacology
MH  - Heparin/*administration & dosage/*chemistry
MH  - Lactic Acid
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Mice, Nude
MH  - Microspheres
MH  - Neovascularization, Physiologic/drug effects
MH  - Polyglycolic Acid
MH  - Polylactic Acid-Polyglycolic Acid Copolymer
MH  - Polymers
MH  - Porosity
EDAT- 2006/07/22 09:00
MHDA- 2007/01/06 09:00
CRDT- 2006/07/22 09:00
PHST- 2006/02/28 00:00 [received]
PHST- 2006/04/13 00:00 [accepted]
PHST- 2006/07/22 09:00 [pubmed]
PHST- 2007/01/06 09:00 [medline]
PHST- 2006/07/22 09:00 [entrez]
AID - 10.1007/s11095-006-9039-9 [doi]
PST - ppublish
SO  - Pharm Res. 2006 Aug;23(8):1835-41. doi: 10.1007/s11095-006-9039-9.